Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Van der Jeught

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Scientific Reports|March 3, 2016
Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumoursLukasz Bialkowski, Alexia van Weijnen, Kevin Van der Jeught, et al.
Nature Nanotechnology|January 19, 2020
Author Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancerJiangsheng Xu, Yunhua Liu, Yujing Li, et al.
Nature Nanotechnology|February 27, 2019
Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancerJiangsheng Xu, Yunhua Liu, Yujing Li, et al.
Nature Nanotechnology|March 7, 2019
Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancerJiangsheng Xu, Yunhua Liu, Yujing Li, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 5, 2023
A T Cell-Engaging Tumor Organoid Platform for Pancreatic Cancer ImmunotherapyZhuolong Zhou, Kevin Van der Jeught, Yujing Li, et al.
Science Translational Medicine|February 11, 2021
Targeted immunotherapy for HER2-low breast cancer with 17p lossYujing Li, Yifan Sun, Michael Kulke, et al.
Gastro Hep Advances|December 15, 2023
Colorectal Cancer Immunotherapy: State of the Art and Future DirectionsAlyssa Mauri Cornista, Maria Virginia Giolito, Kristi Baker, et al.
Oncotarget|August 25, 2014
A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in miceTherese Liechtenstein, Noemi Perez-Janices, Maria Gato, et al.
Cancer Immunology Research|December 15, 2015
Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic CellsSandra Van Lint, Dries Renmans, Katrijn Broos, et al.
JCI Insight|June 22, 2026
IL1RAP-expressing myeloid-stromal networks represent a therapeutic vulnerability to improve chemoimmunotherapy sensitivity in pancreatic cancerErin M Dickey, Harper M Marsh, Camilla Rydberg-Millrud, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Scientific Reports|March 3, 2016
Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumoursLukasz Bialkowski, Alexia van Weijnen, Kevin Van der Jeught, et al.
Nature Nanotechnology|January 19, 2020
Author Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancerJiangsheng Xu, Yunhua Liu, Yujing Li, et al.
Nature Nanotechnology|February 27, 2019
Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancerJiangsheng Xu, Yunhua Liu, Yujing Li, et al.
Nature Nanotechnology|March 7, 2019
Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancerJiangsheng Xu, Yunhua Liu, Yujing Li, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 5, 2023
A T Cell-Engaging Tumor Organoid Platform for Pancreatic Cancer ImmunotherapyZhuolong Zhou, Kevin Van der Jeught, Yujing Li, et al.
Science Translational Medicine|February 11, 2021
Targeted immunotherapy for HER2-low breast cancer with 17p lossYujing Li, Yifan Sun, Michael Kulke, et al.
Gastro Hep Advances|December 15, 2023
Colorectal Cancer Immunotherapy: State of the Art and Future DirectionsAlyssa Mauri Cornista, Maria Virginia Giolito, Kristi Baker, et al.
Oncotarget|August 25, 2014
A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in miceTherese Liechtenstein, Noemi Perez-Janices, Maria Gato, et al.
Cancer Immunology Research|December 15, 2015
Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic CellsSandra Van Lint, Dries Renmans, Katrijn Broos, et al.
JCI Insight|June 22, 2026
IL1RAP-expressing myeloid-stromal networks represent a therapeutic vulnerability to improve chemoimmunotherapy sensitivity in pancreatic cancerErin M Dickey, Harper M Marsh, Camilla Rydberg-Millrud, et al.
Pageof 4